Kimber L Stanhope1, Jean-Marc Schwarz, Peter J Havel. 1. Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, Davis, California 95616, USA. klstanhope@ucdavis.edu
Abstract
PURPOSE OF REVIEW: The effects of dietary sugar on risk factors and the processes associated with metabolic disease remain a controversial topic, with recent reviews of the available evidence arriving at widely discrepant conclusions. RECENT FINDINGS: There are many recently published epidemiological studies that provide evidence that sugar consumption is associated with metabolic disease. Three recent clinical studies, which investigated the effects of consuming relevant doses of sucrose or high-fructose corn syrup along with ad libitum diets, provide evidence that consumption of these sugars increase the risk factors for cardiovascular disease and metabolic syndrome. Mechanistic studies suggest that these effects result from the rapid hepatic metabolism of fructose catalyzed by fructokinase C, which generates substrate for de novo lipogenesis and leads to increased uric acid levels. Recent clinical studies investigating the effects of consuming less sugar, via educational interventions or by substitution of sugar-sweetened beverages for noncalorically sweetened beverages, provide evidence that such strategies have beneficial effects on risk factors for metabolic disease or on BMI in children. SUMMARY: The accumulating epidemiological evidence, direct clinical evidence, and the evidence suggesting plausible mechanisms support a role for sugar in the epidemics of metabolic syndrome, cardiovascular disease, and type 2 diabetes.
PURPOSE OF REVIEW: The effects of dietary sugar on risk factors and the processes associated with metabolic disease remain a controversial topic, with recent reviews of the available evidence arriving at widely discrepant conclusions. RECENT FINDINGS: There are many recently published epidemiological studies that provide evidence that sugar consumption is associated with metabolic disease. Three recent clinical studies, which investigated the effects of consuming relevant doses of sucrose or high-fructosecorn syrup along with ad libitum diets, provide evidence that consumption of these sugars increase the risk factors for cardiovascular disease and metabolic syndrome. Mechanistic studies suggest that these effects result from the rapid hepatic metabolism of fructose catalyzed by fructokinase C, which generates substrate for de novo lipogenesis and leads to increased uric acid levels. Recent clinical studies investigating the effects of consuming less sugar, via educational interventions or by substitution of sugar-sweetened beverages for noncalorically sweetened beverages, provide evidence that such strategies have beneficial effects on risk factors for metabolic disease or on BMI in children. SUMMARY: The accumulating epidemiological evidence, direct clinical evidence, and the evidence suggesting plausible mechanisms support a role for sugar in the epidemics of metabolic syndrome, cardiovascular disease, and type 2 diabetes.
Authors: Karen L Teff; Sharon S Elliott; Matthias Tschöp; Timothy J Kieffer; Daniel Rader; Mark Heiman; Raymond R Townsend; Nancy L Keim; David D'Alessio; Peter J Havel Journal: J Clin Endocrinol Metab Date: 2004-06 Impact factor: 5.958
Authors: Jaimie N Davis; Kim-Anne Lê; Ryan W Walker; Susanna Vikman; Donna Spruijt-Metz; Marc J Weigensberg; Hooman Allayee; Michael I Goran Journal: Am J Clin Nutr Date: 2010-10-20 Impact factor: 7.045
Authors: Kerry L Donnelly; Coleman I Smith; Sarah J Schwarzenberg; Jose Jessurun; Mark D Boldt; Elizabeth J Parks Journal: J Clin Invest Date: 2005-05 Impact factor: 14.808
Authors: Lawrence de Koning; Vasanti S Malik; Mark D Kellogg; Eric B Rimm; Walter C Willett; Frank B Hu Journal: Circulation Date: 2012-03-12 Impact factor: 29.690
Authors: Chad L Cox; Kimber L Stanhope; Jean Marc Schwarz; James L Graham; Bonnie Hatcher; Steven C Griffen; Andrew A Bremer; Lars Berglund; John P McGahan; Nancy L Keim; Peter J Havel Journal: Nutr Metab (Lond) Date: 2012-07-24 Impact factor: 4.169
Authors: Thomas Jensen; Manal F Abdelmalek; Shelby Sullivan; Kristen J Nadeau; Melanie Green; Carlos Roncal; Takahiko Nakagawa; Masanari Kuwabara; Yuka Sato; Duk-Hee Kang; Dean R Tolan; Laura G Sanchez-Lozada; Hugo R Rosen; Miguel A Lanaspa; Anna Mae Diehl; Richard J Johnson Journal: J Hepatol Date: 2018-02-02 Impact factor: 25.083
Authors: U Masharani; P Sherchan; M Schloetter; S Stratford; A Xiao; A Sebastian; M Nolte Kennedy; L Frassetto Journal: Eur J Clin Nutr Date: 2015-04-01 Impact factor: 4.016
Authors: Rafael Moncada; Sara Becerril; Amaia Rodríguez; Leire Méndez-Giménez; Beatriz Ramírez; Victoria Catalán; Javier Gómez-Ambrosi; M Jesús Gil; Secundino Fernández; Javier A Cienfuegos; Víctor Valentí; Gema Frühbeck Journal: Obes Surg Date: 2016-07 Impact factor: 4.129